ANALYSIS: BIOSECURE Act — Trump encircles Chinese biotechs linked to Iran

Introduction: A silent war in the laboratories

The regulatory weapon steps out of the shadows

In June 2026, the Trump administration crossed a decisive threshold in the economic war against China: WuXi AppTec, a Chinese giant in biopharmaceutical services, was placed on restricted federal contract lists through the BIOSECURE Act embedded in the NDAA 2026. This is no symbolic sanction. It is a lock on the global pharmaceutical supply chain that directly implicates hundreds of American companies.

In parallel, subsidiaries of the BGI Group — the already-controversial Chinese genomics conglomerate — were targeted by expanded export controls. The convergence of biotech pressure, Iran policy, and Sino-American technological rivalry is drawing a new geography of risk that few analysts had anticipated at this scale.

The Iran-China axis in Washington's crosshairs

What makes this sequence particularly significant is its geopolitical context: $300 billion in Iranian reconstruction is at stake if a final deal with Washington is reached. Yet experts are warning of a massive risk of technological re-export to China via Tehran — a sanctions-circumvention channel that American lawmakers intend to shut down now.

The Pentagon expanded the 1260H list by 17 additional Chinese companies on June 8, 2026, including names as prominent as Alibaba, BYD, and Baidu. Beijing's response was swift: on June 22, 2026, China sanctioned 46 American firms in direct retaliation. A symmetrical escalation that illustrates the brutality of this simmering economic war.

The BIOSECURE Act: anatomy of a pivotal law

A text long in the making, formidable in application

The BIOSECURE Act took several years to find its definitive legislative form. First introduced under a prior Congress, it was ultimately embedded in the National Defense Authorization Act 2026 — the United States' main military programming law. Its principle: prohibiting federal agencies from contracting with Chinese biotechnology companies deemed threatening to national security.

The list of targeted companies includes WuXi AppTec, WuXi Biologics, BGI Genomics, MGI Tech, and Complete Genomics. These firms represent a considerable share of global contract drug manufacturing, genomic sequencing, and biopharmaceutical development capacity. Their exclusion from American federal contracts creates immediate pressure on their clients — including numerous Western pharmaceutical groups.

1260H-listed companies excluded from DoD contracts

As of June 30, 2026, companies on the Pentagon's 1260H list are formally excluded from direct contracts with the Department of Defense. This list, which grew by 17 new entries on June 8, now includes Chinese players in technology, energy, mobility, and artificial intelligence. It is a mapping of the threat as perceived by Washington.

The inclusion of Alibaba, BYD, and Baidu on this list sends a strong signal: Washington is no longer limiting itself to defense or telecommunications companies. The technological war has shifted terrain — it has settled at the heart of the civilian economy, in medical data, electric batteries, and search algorithms.

BGI: the genomics group at the center of the storm

Genetic data as a strategic stake

BGI Genomics is no ordinary company. Founded in Beijing, it has become one of the world's largest genomic sequencing centers, with tentacles in COVID testing, medical databases, and human genome research. For Washington, the problem is fundamental: the genetic data collected by BGI is potentially accessible to the Chinese Communist Party under China's national security laws.

The expanded export controls on BGI's biotech subsidiaries — notably MGI Tech and Complete Genomics — aim to cut these entities' access to American equipment and dual-use technologies. The measure is particularly targeted at genomic sequencers and biological reagents. In diplomatic language, this is called "export controls." In strategic language, it is a partial technology embargo.

The global pharmaceutical chain in recomposition

The impact on the global pharmaceutical industry cannot be understated. WuXi AppTec manufactures active pharmaceutical ingredients and antibodies for dozens of American and European groups. Its exclusion from federal contracts forces those groups into a painful choice: forgo American public markets or find alternative suppliers on very short timelines.

This forced recomposition of the global biomedical supply chain is part of a broader trend of pharmaceutical reshoring promoted by Washington since the COVID crisis. But the pace imposed by the BIOSECURE Act far exceeds the natural rhythm of this rebalancing — creating capacity tensions in sectors already under pressure.

Beijing's counterstrike: 46 American firms sanctioned

A calculated symmetry

On June 22, 2026, Beijing struck back: 46 American firms were placed on Chinese export control lists and excluded from Chinese public procurement. The symmetry is no accident — it is a diplomatic message: Washington does not hold the monopoly on economic retaliation.

The companies targeted by Beijing span similar strategic sectors: defense technology, semiconductors, communications equipment. China also reinforced its own lists of "unreliable entities," reactivating a mechanism that had been little used until then. This symmetrical escalation confirms that both powers have entered a phase of structured economic warfare, with implicit rules but very real consequences.

The domino effect on Western allies

This bilateral conflict has direct repercussions for Washington's European and Asian allies. British, German, and Japanese pharmaceutical groups that depend on the Chinese supply chain now find themselves caught between Washington's demands and Beijing's retaliatory measures. The CRINK axis — the academic acronym designating the strategic convergence of China, Russia, Iran, and North Korea — is at the heart of CSIS strategic analysis.

For NATO allies, Washington's message is clear: technological dependence on China is a collective security vulnerability. Decoupling will never be comfortable. But according to current American doctrine, it is inevitable. This pressure compounds the rising demands for defense spending — European allies and Canada already increased their defense spending by $90 billion in 2025.

The Iranian risk: $300 billion in reconstruction under surveillance

A peace deal that opens a technological Pandora's box

If the Iran-USA deal materializes into a final agreement, estimates point to $300 billion in reconstruction needs for an Iranian economy bled dry after decades of sanctions. This colossal figure attracts multiple interests — and raises a major strategic concern in Washington: the re-export of technology to China via Iran.

The feared scenario is documented by analysts at 19FortyFive: American or Western equipment sold legally to Iran as part of its reconstruction could be diverted to Beijing, circumventing export controls. Iran, Russia, China, and North Korea — the strategic adversary axis — is watching the terms of any deal with particular attention to its technological implications.

Washington locks the doors before opening them

It is precisely to prevent this risk that the Trump administration accelerated implementation of the BIOSECURE Act and the expansion of the 1260H list before any normalization of relations with Tehran. The logic is coherent: better to put the locks in place now, while the Iranian negotiating leverage is at its peak, than to try to impose them after an agreement in which Tehran would have legitimate expectations of commercial opening.

This legislative anticipation is a form of diplomatic sophistication not always associated with the Trump 2.0 administration in media commentary. Yet on this precise issue, the BIOSECURE Act → 1260H list → Iran MOU sequence reveals an undeniable strategic coherence. Granting Tehran an economic window while closing the leak channels to Beijing — that is shrewd.

The CRINK axis: convergence of threats under academic scrutiny

CSIS maps the new geopolitics of adversaries

The Center for Strategic and International Studies (CSIS) has formalized under the acronym CRINK the strategic convergence between China, Russia, Iran, and North Korea. This analysis, published in June 2026, goes beyond simple "Axis of Evil" rhetoric — it documents concrete technology transfers, measurable military cooperation, and UN voting alignments that sketch an architecture of opposition to the Western-led international order.

For Washington, this convergence justifies a global and coordinated approach to sanctions and export controls. Iran, Russia, China, and North Korea can no longer be treated as separate problems. Pressure on one reverberates onto the others. The BIOSECURE Act and the 1260H list fit squarely within this logic of systemic pressure on the entire CRINK network.

Silicon Valley caught in the geopolitical vise

For the American technology industry, this new doctrine is an existential challenge. The $1.15 billion invested by JCET — a Chinese chip-packaging company — illustrates how deeply semiconductor value chains remain intertwined between China and the West despite all the decoupling rhetoric. The Silk Bulletin report of June 23, 2026 documents these persistent financial flows.

Silicon Valley finds itself torn between its dependence on the vast Chinese market and supply chain on one side, and Washington's growing compliance demands on the other. American semiconductor companies that sell to China now risk being targeted themselves by secondary sanctions if their technologies end up in military systems or surveillance programs.

Impact on alliances and the global pharmaceutical chain

Europe facing a choice

For European allies, the BIOSECURE Act poses a direct strategic question: should they adopt similar legislation to stay aligned with Washington, at the risk of disrupting their own pharmaceutical supply chains? Several European groups have already begun auditing their dependencies on WuXi AppTec and BGI — not because the law requires it, but because American regulatory pressure creates contractual and reputational risks.

This transatlantic regulatory harmonization — implicit rather than explicit — is one of the most important dynamics in current technological geopolitics. It is happening without any formal agreement, through the simple alignment of economic incentives. European companies that want access to American markets have no choice but to apply American standards on supply chain security.

American patients in the equation

Beyond geopolitics, there is a concrete reality: millions of American patients depend on drugs whose active ingredients are manufactured in China, often by companies like WuXi AppTec. The disruption of this supply chain has a real human cost. The FDA has already issued alerts about shortage risks in certain therapeutic classes if the transition to alternative suppliers is not managed with sufficient lead time.

The Trump administration has responded to these concerns by framing pharmaceutical reshoring as a national security priority. But building domestic pharmaceutical manufacturing capacity takes years and tens of billions of dollars in investment. Between the stated ambition and the industrial reality, the gap remains immense — and patients will be the first to suffer if the transitions are mismanaged.

Perspectives and stakes for the world order

A regulatory precedent with lasting consequences

The BIOSECURE Act and the expansion of the 1260H list constitute a major regulatory precedent in the history of international economic relations. For the first time, the United States is systematically using its public procurement as a lever for technological decoupling in sectors as fundamental as biotechnology and genomics. This model, once established, will be difficult to undo — regardless of the outcome of future elections.

Financial markets have partially priced in this risk. WuXi AppTec and BGI valuations have taken significant hits since the BIOSECURE Act announcement. But the deeper question — who will manufacture the drugs of the future, in which country, under which jurisdiction — remains wide open. The answer will determine a substantial share of twenty-first-century power balances.

The race for biotechnological sovereignty

Beyond the immediate sanctions, the real competition is over biotechnological sovereignty. The United States, the European Union, Japan, and Australia are investing heavily in creating national or allied capacity for biopharmaceutical research and manufacturing. China is doing the same. This is not a return to naive protectionism — it is a recognition that critical dependencies in the domains of health and biology are unacceptable strategic vulnerabilities.

The convergence between national security and industrial policy is now openly assumed and claimed by all major powers. Pure free trade is in retreat. What is emerging resembles a selective globalism — commercial openness in non-strategic sectors, defensive closure in domains deemed critical. The challenge for the coming decades will be defining where the strategic ends and the economic begins.

What the BIOSECURE Act and the 1260H list sketch in filigree is the emergence of two distinct technological spheres: a Western sphere and a Sino-Russian sphere. These spheres will not be hermetically sealed — commercial exchanges will persist — but they will have their own standards, their own critical infrastructure, their own supply chains. Biotechnology, genomics, and semiconductors are the first domains where this bifurcation becomes visible and regulated.

This bifurcation is not inevitable across all sectors. Areas like agri-food, tourism, or certain consumer goods will probably remain globally integrated. But in domains touching national security, public health, and sensitive data, separation is now a deliberate Washington policy — and one that will be all the harder to reverse as it institutionalizes itself in legislation like the BIOSECURE Act.

For multinational corporations — American, European, or Asian — this bifurcation creates unprecedented strategic dilemmas. Choosing a technological camp is becoming an existential decision. Pharmaceutical groups that depend on both American markets and the Chinese supply chain must now calculate the cost of belonging to one sphere or the other. The cost of decoupling will be partly transferred to consumers, patients, and shareholders — and partly absorbed by states subsidizing it through national industrial policies.

European allies face a particularly difficult version of this dilemma. The European Union built its prosperity on global commercial openness — with China as a crucial partner. But it is also bound to Washington by defense treaties that create regulatory compliance obligations. Navigating between the two without tearing apart requires a diplomatic and industrial sophistication that not all European capitals have yet developed to the level the stakes demand.

Conclusion: The biotech war is declared, and patients are paying the price

A historic turning point in the regulation of global biotechnology

The BIOSECURE Act of 2026 is not a stopgap measure. It marks a historic turning point in the global governance of biotechnology. For the first time, a major power is using its public purchasing power to deliberately restructure global biopharmaceutical supply chains along national security criteria. WuXi AppTec, BGI, the 1260H list — these names will remain in political economy textbooks for decades to come as symbols of an era when biology became a geopolitical weapon.

China and Iran are watching this American move with equal attention. Russia is drawing its own lessons from the post-2022 sanctions. The CRINK convergence is not only defensive — it is building its own alternative supply chains, its own technological standards, its own decoupling architecture. What we observe today is the beginning of a global technological bifurcation whose consequences will extend well beyond the domain of biotechnology.

A call for lucidity and precision

Facing this reality, clarity is essential. National security is a legitimate argument — but it can also become a screen for protectionism, discrimination, and irresponsible disruption of healthcare systems. Washington must wage this technological war with surgical precision, distinguishing real threats from benign dependencies, protecting American patients from the consequences of rushed transitions.

The West has the means to win this biotechnological competition — it has fundamental research, capital, and talent. But winning does not mean destroying what was built over thirty years of integrated supply chains. The task is to rebuild intelligently, not to dismantle brutally.

Signed Maxime Marquette, columnist

Columnist's transparency box

Positioning and method

This article is an opinion analysis based exclusively on facts documented by the sources cited at the bottom of the page. I am not a biotechnology specialist, but I have been covering geopolitical and economic dynamics for several years. My analysis reflects my reading of the available facts, not pharmaceutical or scientific expertise.

I have no connection to WuXi AppTec, BGI, pharmaceutical groups, or governments cited in this article. All positions expressed in the editorial passages are my own and represent only my views. No facts were invented — every figure comes from a dated, verifiable source.

Limits of the analysis

This analysis is based on information available through June 25, 2026. The geopolitical situation is evolving rapidly. Developments on the Iran-USA deal, Chinese countermeasures, and BIOSECURE Act implementation may significantly alter this analysis in the weeks ahead. Readers are encouraged to consult the primary sources cited for up-to-date information.

I also acknowledge that the human and medical implications of technological decoupling would merit an article in their own right — I have only sketched their outlines here. The complexity of this subject far exceeds the scope of a single article.

Sources

Primary sources

Claw Street Journal — BIOSECURE Act, 1260H list, BGI, WuXi AppTec — June 21, 2026

CNBC — China sanctions 46 American firms in retaliation — June 22, 2026

19FortyFive — The Iran deal does not stop at Iran, Russia-China-North Korea are watching — June 19, 2026

Secondary sources

Geopolitical Daily — China-USA sanctions counterstrike — June 22, 2026

CSIS — CRINK Axis: China, Russia, Iran, North Korea — June 25, 2026

Silk Bulletin No. 137 — JCET chip packaging $1.15 billion — June 23, 2026